Annuncio • Apr 03
Amyris, Inc. announced delayed annual 10-K filing On 04/02/2024, Amyris, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Annuncio • Jan 24
Third Amended Joint Reorganization Plan Filed by Amyris, Inc. Amyris, Inc. filed third amended joint plan of reorganization in the US Bankruptcy Court on January 22, 2024. As per the plan filed, there is no change in treatment of any claim class or source of funding. Amyris, Inc. filed modified third amended joint plan of reorganization in the US Bankruptcy Court on January 23, 2024. As per the plan filed, there is no change in treatment of any claim class or source of funding. Annuncio • Jan 06
Foris Ventures Provides Information to the Shareholders On January 5, 2024, Foris Ventures, LLC announced that it has been in discussion with members of the Company’s management and Board in connection with the Chapter 11 Cases and other strategic alternatives and may continue to be in contact with members of the Company’s management, members of the Board, shareholders, advisors and other relevant parties regarding any alternatives that the Company could employ in the Chapter 11 Cases or otherwise. Foris Ventures may take positions with respect to potential changes in the operations, management, Board composition, ownership, capital structure, strategy and future plans of the Company. In addition to its role with respect to the DIP Credit Agreement, Foris Ventures may consider participating in transactions that are part of the Chapter 11 Cases, including as part of the Company’s reorganization efforts and/or sales of significant Company assets. Annuncio • Dec 28
Amyris, Inc. Announces Resignation of Elizabeth Dreyer as Chief Accounting Officer and Corporate Controller, Effective as of January 2, 2024 Amyris, Inc. announced that on December 20, 2023, Elizabeth Dreyer notified the Company of her decision to resign from her position as the Company’s Chief Accounting Officer and Corporate Controller effective as of January 2, 2024 (the “Resignation Date”) to take up a similar role at another publicly listed company. Ms. Dreyer’s resignation is not due to any disagreements on the Company’s financial statement disclosures, internal controls or accounting policies or practices. Ms. Dreyer will assist the Company with the transition of her duties and responsibilities. Annuncio • Nov 14
Amyris, Inc. announced delayed 10-Q filing On 11/13/2023, Amyris, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Annuncio • Sep 08
Nasdaq to Delist the Common Stock of Amyris On September 7, 2023, The Nasdaq Stock Market announced that it will delist the common stock of Amyris, Inc. Amyris, Inc.’s securities were suspended on August 21, 2023, and have not traded on Nasdaq since that time. Annuncio • Sep 02
Amyris, Inc. Appoints Scott White as A Class II Director On August 29, 2023, Amyris Inc. appointed Scott White as a Class II director, effective immediately, and with a term expiring at the company’s 2024 annual meeting of stockholders. The board determined that Mr. White qualifies as an independent director pursuant to the listing standards of the Nasdaq Stock Market. Mr. White will serve as a member of the Restructuring Committee of the Board. Mr. White is currently President and Chief Executive Officer of Edsal Manufacturing, where he has served since 2019. Mr. White has over 30 years of experience in global finance, marketing and general management roles. Prior to joining Edsal, from 2016 to 2019, Mr. White served as CEO of New Avon, a leading provider of cosmetics and beauty products. Prior to that, from 2005 to 2016, he held multiple senior management roles over 10 years at Abbott Laboratories, including President of Abbott Nutrition International. Mr. White began his career at Procter & Gamble where he served for 15 years. Mr. White currently serves as a member of the board of directors of Edsal, a privately held company. Mr. White holds an M.B.A. from Northwestern University Kellogg School of Management and a B.S. in Finance from Miami University. Annuncio • Aug 12
Amyris' Common Stock To Be Delisted from Nasdaq As previously disclosed, on August 10, 2023, Amyris, Inc. (the “Company”) and certain of its direct and indirect subsidiaries filed a voluntary petition for relief (the “Chapter 11 Cases”) under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware. On August 10, 2023, the Company received written notice (the “Delisting Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, as a result of the Chapter 11 Cases and in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, Nasdaq had determined that the Company’s common stock will be delisted from Nasdaq. In the Delisting Notice, the staff of Nasdaq referenced the Chapter 11 Filings and associated public concerns raised by them, concerns regarding the residual equity interest of the existing listed securities holders and concerns about the Company's ability to sustain compliance with all requirements for continued listing on Nasdaq. The Delisting Notice also indicates that the Company may appeal Nasdaq’s determination pursuant to procedures set in Nasdaq Listing Rule 5800 Series. The Company does not intend to appeal this determination. Trading of the Company’s common stock will be suspended at the opening of business on August 21, 2023 and a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove the Company’s securities from listing and registration on Nasdaq. New Risk • Aug 11
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: €22.2m (US$24.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$540m free cash flow). Share price has been highly volatile over the past 3 months (32% average weekly change). Negative equity (-US$648m). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$159m net loss in 2 years). Shareholders have been diluted in the past year (15% increase in shares outstanding). Market cap is less than US$100m (€22.2m market cap, or US$24.3m). Annuncio • May 29
Amyris Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement On May 26, 2023, Amyris, Inc. received a deficiency letter from the Nasdaq Listing Qualifications Department (the ‘Staff’) of The Nasdaq Stock Market LLC (‘Nasdaq’) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the ‘Minimum Bid Price Requirement’). The Nasdaq deficiency letter has no immediate effect on the listing of the Company’s common stock which will continue to trade on The Nasdaq Global Select Market under the symbol ‘AMRS’. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until November 22, 2023, to regain compliance with the Minimum Bid Price Requirement. If at any time before November 22, 2023, the bid price of the Company’s common stock closes at $1.00 per share or more for a minimum of ten consecutive business days, the Staff will provide written confirmation that the Company has achieved compliance. If the Company does not regain compliance with the Minimum Bid Price Requirement by November 22, 2023, the Company’s common stock will become subject to delisting. In the event that the Company receives notice that its common stock is being delisted, the Nasdaq listing rules permit the Company to appeal a delisting determination by the Staff to a hearings panel. The Company intends to monitor the bid price of its common stock and consider available options if its common stock does not trade at a level likely to result in the Company regaining compliance with Nasdaq’s minimum bid price rule by November 22, 2023, including such options as effecting a reverse stock split. Reported Earnings • May 10
First quarter 2023 earnings released: US$0.53 loss per share (vs US$0.34 loss in 1Q 2022) First quarter 2023 results: US$0.53 loss per share (further deteriorated from US$0.34 loss in 1Q 2022). Revenue: US$56.1m (down 2.8% from 1Q 2022). Net loss: US$193.3m (loss widened 80% from 1Q 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 3.0% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings. Buying Opportunity • Apr 26
Now 24% undervalued after recent price drop Over the last 90 days, the stock is down 52%. The fair value is estimated to be €0.95, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 20% over the last 3 years. Earnings per share has grown by 36%. For the next 3 years, revenue is forecast to grow by 16% per annum. Earnings is also forecast to grow by 31% per annum over the same time period. Reported Earnings • Mar 18
Full year 2022 earnings released: US$1.65 loss per share (vs US$0.93 loss in FY 2021) Full year 2022 results: US$1.65 loss per share (further deteriorated from US$0.93 loss in FY 2021). Revenue: US$269.8m (down 21% from FY 2021). Net loss: US$528.5m (loss widened 95% from FY 2021). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 2.0% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. Breakeven Date Change • Mar 18
No longer forecast to breakeven The 6 analysts covering Amyris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$114.3m in 2025. New consensus forecast suggests the company will make a loss of US$43.8m in 2025. Annuncio • Jan 31
Amyris Launches 4U by Tia™ Haircare Line Exclusively At Walmart Amyris, Inc. announced the launch of 4U by TiaTM, a new haircare line available exclusively at Walmart. Founded by actress and entrepreneur Tia Mowry, 4U by Tia will be sold in over 2,800 Walmart retail stores in the U.S, on Walmart.com, and on the direct-to-consumer website 4UbyTia.com. Amyris will be operating the brand as part of its clean beauty portfolio of brands. The brand is launching with a full line of eight products formulated for 2A to 4C (curly) hair, all of which contain Amyris' patented Hemi15TM, a breakthrough ingredient that nourishes and protects textured hair. The line is 100% vegan, silicone-free, sulfate-free and paraben-free. Hemi15 is created using Amyris' proprietary Lab-to-Market platform, which leverages precision fermentation to create molecules that are bioidentical to those found in nature and traditionally derived from finite sources (including animals, plants, or petrochemicals) to create sustainable ingredients and provide better, healthier options for the products people use every day. Breakeven Date Change • Nov 16
No longer forecast to breakeven The 7 analysts covering Amyris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$7.18m in 2024. New consensus forecast suggests the company will make a loss of US$28.4m in 2024. Breakeven Date Change • Nov 11
No longer forecast to breakeven The 7 analysts covering Amyris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$7.18m in 2024. New consensus forecast suggests the company will make a loss of US$78.1m in 2024. Reported Earnings • Nov 10
Third quarter 2022 earnings released: US$0.50 loss per share (vs US$0.11 loss in 3Q 2021) Third quarter 2022 results: US$0.50 loss per share (further deteriorated from US$0.11 loss in 3Q 2021). Revenue: US$71.1m (up 49% from 3Q 2021). Net loss: US$161.4m (loss widened 390% from 3Q 2021). Revenue is forecast to grow 43% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings. Breakeven Date Change • Nov 09
Forecast to breakeven in 2024 The 7 analysts covering Amyris expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 45% per year to 2023. The company is expected to make a profit of US$54.2m in 2024. Average annual earnings growth of 88% is required to achieve expected profit on schedule. Recent Insider Transactions • Sep 09
CFO & Chief Administration Officer recently sold €74k worth of stock On the 2nd of September, Hermanus Kieftenbeld sold around 26k shares on-market at roughly €2.86 per share. This transaction amounted to 20% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €116k. Hermanus has been a net seller over the last 12 months, reducing personal holdings by €150k. Recent Insider Transactions • Aug 18
President recently bought €68k worth of stock On the 15th of August, John Melo bought around 17k shares on-market at roughly €3.96 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent buy, John has been a net seller over the last 12 months, reducing personal holdings by €48k. Reported Earnings • Aug 11
Second quarter 2022 earnings released: US$0.34 loss per share (vs US$0.048 profit in 2Q 2021) Second quarter 2022 results: US$0.34 loss per share (down from US$0.048 profit in 2Q 2021). Revenue: US$65.2m (up 25% from 2Q 2021). Net loss: US$110.0m (down US$125.4m from profit in 2Q 2021). Over the next year, revenue is forecast to grow 91%, compared to a 3.6% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Breakeven Date Change • Aug 11
Forecast to breakeven in 2024 The 8 analysts covering Amyris expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 33% per year to 2023. The company is expected to make a profit of US$7.18m in 2024. Average annual earnings growth of 79% is required to achieve expected profit on schedule. Recent Insider Transactions • Jul 09
President recently sold €116k worth of stock On the 6th of July, John Melo sold around 56k shares on-market at roughly €2.08 per share. This was the largest sale by an insider in the last 3 months. This was John's only on-market trade for the last 12 months. Recent Insider Transactions • Jun 06
CFO & Chief Administration Officer recently sold €76k worth of stock On the 2nd of June, Hermanus Kieftenbeld sold around 35k shares on-market at roughly €2.18 per share. This was the largest sale by an insider in the last 3 months. Hermanus has been a seller over the last 12 months, reducing personal holdings by €382k. Annuncio • May 04
Amyris, Inc. to Report Q1, 2022 Results on May 10, 2022 Amyris, Inc. announced that they will report Q1, 2022 results Pre-Market on May 10, 2022 Annuncio • Apr 24
Amyris, Inc. (NasdaqGS:AMRS) entered into an Agreement and Plan of Merger and Reorganization to acquire Onda Beauty Inc. Amyris, Inc. (NasdaqGS:AMRS) entered into an Agreement and Plan of Merger and Reorganization to acquire Onda Beauty Inc. on April 11, 2022. The consideration consists of 907,946 shares of the common stock of Amyris, Inc. Fenwick & West LLP acted as legal advisor for Amyris. Annuncio • Apr 12
Amyris, Inc., Annual General Meeting, May 27, 2022 Amyris, Inc., Annual General Meeting, May 27, 2022, at 14:00 Pacific Standard Time. Agenda: To consider election of three Class III Directors to serve for a three-year term; to consider ratification of the appointment of Independent Registered Public Accounting Firm; and to consider approval of amendment to Certificate of Incorporation to increase authorized shares. Annuncio • Mar 04
Amyris, Inc. announced delayed annual 10-K filing On 03/02/2022, Amyris, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Annuncio • Feb 24
Amyris, Inc. to Report Q4, 2021 Results on Mar 01, 2022 Amyris, Inc. announced that they will report Q4, 2021 results Pre-Market on Mar 01, 2022 Annuncio • Feb 10
Amyris, Inc. (NasdaqGS:AMRS) completed the acquisition of 70% of EcoFabulous Cosmetics. Amyris, Inc. (NasdaqGS:AMRS) agreed to acquire 70% of EcoFabulous Cosmetics on April 15, 2021. Marissa will join Amyris to lead brand innovation and be the Chief Creative Officer for the EcoFabulous brand.
Amyris, Inc. (NasdaqGS:AMRS) completed the acquisition of 70% of EcoFabulous Cosmetics on February 9, 2022. Annuncio • Dec 11
Federman & Sherwood Announces Certification of Securities Class Action Lawsuit Against Amyris, Inc Federman & Sherwood announced that on December 8, 2021, a class action lawsuit was certified in the United States District Court for the Northern District of California against Amyris, Inc. its CEO John Melo, and its former CFO Kathleen Valiasek. The court certified a Class of investors who purchased shares of Amyris, Inc. common stock during the period from March 15, 2018 through March 19, 2019 (the Class Period) and who were damaged thereby. The lawsuit alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations that defendants issued a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class Period. The lawsuit seeks to recover damages on behalf of Amyris, Inc. investors who purchased common stock during the Class Period and are therefore a member of the Class. Annuncio • Nov 24
Amyris, Inc. Provides Revenue Guidance for the Full Year 2021 Amyris, Inc. provides revenue guidance for the full year 2021. For the year, the company expects revenue estimate of $330 million to $370 million. Annuncio • Aug 27
Amyris, Inc. and Jonathan Van Ness Launch JVN Hair A Transformation in Clean Hair Products Amyris, Inc. announced the launch of JVN™, a clean hair products brand. The launch is the third of three highly anticipated brand launches Amyris is introducing to the market this summer. The JVN haircare line is a collaboration between Amyris and Jonathan Van Ness: hair stylist, Emmy-nominated television personality, New York Times best-selling author and podcaster. The JVN line sees all beauty, serves all beauty and honors the uniqueness of each person. The JVN collection features four accessibly priced, best performing in category product families that are silicone-free, color-safe, sulfate-free, cruelty-free, and vegan: Nurture, for hair that deserves extra moisture; Undamage, for hair that is stressed or overtreated, Embody, for fine hair with big dreams; and Complete, for hair that is ready to style. Annuncio • Aug 21
Amyris Achieves Promising In-Vivo Results For Intranasal Delivery Of RNA/NLC Vaccine Amyris, Inc. announced promising in-vivo results in a study of its licensed RNA vaccine through intranasal delivery, developed in collaboration with the Infectious Disease Research Institute (IDRI). Current mRNA vaccine technologies are providing limited immunity protection for the upper respiratory system. As a result, vaccinated people may experience viral replication and viral shedding regardless of variants. In-vivo results indicate that, when delivered to the mucosal membranes via intranasal administration, the Amyris/IDRI RNA vaccine generates antibodies and provides upper respiratory protection for SARS-CoV-2 (COVID-19), which Amyris believes has the potential to provide fuller protection against current variants of SARS-CoV-2. The Amyris/IDRI RNA technology may also support the potential for intranasal vaccine delivery that can protect against SARS-CoV-2 and other respiratory diseases, including the flu. If approved and commercialized, the Amyris/IDRI RNA vaccine is targeted to be more accessible to people in underserved countries. In addition, the intranasal vaccine may offer improved upper respiratory protection beyond currently approved vaccines. Amyris will provide a detailed update of the progress of its vaccine platform and a roadmap for scale up and delivery during one of its upcoming investor mini-series webinars. 
